Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 344

1.

Low immunogenicity predicted for emerging avian-origin H7N9: implication for influenza vaccine design.

De Groot AS, Ardito M, Terry F, Levitz L, Ross T, Moise L, Martin W.

Hum Vaccin Immunother. 2013 May;9(5):950-6. doi: 10.4161/hv.24939. Epub 2013 May 1.

2.

Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design.

De Groot AS, Moise L, Liu R, Gutierrez AH, Terry F, Koita OA, Ross TM, Martin W.

Hum Vaccin Immunother. 2014;10(2):256-62. doi: 10.4161/hv.28135. Epub 2014 Feb 13. Review.

3.

H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus.

Rudenko L, Isakova-Sivak I, Donina S.

Vaccine. 2013 Oct 1;31(42):4702-5. doi: 10.1016/j.vaccine.2013.08.040. Epub 2013 Aug 26.

PMID:
23988294
4.

Divergent H7 immunogens offer protection from H7N9 virus challenge.

Krammer F, Albrecht RA, Tan GS, Margine I, Hai R, Schmolke M, Runstadler J, Andrews SF, Wilson PC, Cox RJ, Treanor JJ, García-Sastre A, Palese P.

J Virol. 2014 Apr;88(8):3976-85. doi: 10.1128/JVI.03095-13. Epub 2014 Jan 22.

5.

Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.

Zhang L, Jia N, Li J, Han Y, Cao W, Wang S, Huang Z, Lu S.

Hum Vaccin Immunother. 2014;10(7):1949-58. doi: 10.4161/hv.28795.

6.

Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge.

Schmeisser F, Vasudevan A, Verma S, Wang W, Alvarado E, Weiss C, Atukorale V, Meseda C, Weir JP.

PLoS One. 2015 Jan 28;10(1):e0117108. doi: 10.1371/journal.pone.0117108. eCollection 2015.

7.

Preexisting CD4+ T-cell immunity in human population to avian influenza H7N9 virus: whole proteome-wide immunoinformatics analyses.

Duvvuri VR, Duvvuri B, Alice C, Wu GE, Gubbay JB, Wu J.

PLoS One. 2014 Mar 7;9(3):e91273. doi: 10.1371/journal.pone.0091273. eCollection 2014.

8.

Development and applications of universal H7 subtype-specific antibodies for the analysis of influenza H7N9 vaccines.

Gravel C, Elmgren C, Muralidharan A, Hashem AM, Jaentschke B, Xu K, Widdison J, Arnold K, Farnsworth A, Rinfret A, Van Domselaar G, Wang J, Li C, Li X.

Vaccine. 2015 Feb 25;33(9):1129-34. doi: 10.1016/j.vaccine.2015.01.034. Epub 2015 Jan 22.

PMID:
25620245
9.

Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.

Zhang L, Lu J, Chen Y, Shi F, Yu H, Huang C, Cui L, Shi Z, Jiao Y, Hu Y.

Viruses. 2015 Aug 4;7(8):4369-84. doi: 10.3390/v7082821.

10.

Preparing for a potential A(H7N9) pandemic: lessons from the deployment of A(H1N1) pandemic vaccines.

Nguyen-Van-Tam JS, Sellwood C.

Expert Rev Vaccines. 2013 Aug;12(8):825-8. doi: 10.1586/14760584.2013.814832. No abstract available.

PMID:
23984955
11.

Cross-protective efficacy of baculovirus displayed hemagglutinin against highly pathogenic influenza H7 subtypes.

Prabakaran M, Kumar SR, Raj KV, Wu X, He F, Zhou J, Kwang J.

Antiviral Res. 2014 Sep;109:149-59. doi: 10.1016/j.antiviral.2014.06.017. Epub 2014 Jul 2.

PMID:
24997413
12.

Newly Emergent Highly Pathogenic H5N9 Subtype Avian Influenza A Virus.

Yu Y, Wang X, Jin T, Wang H, Si W, Yang H, Wu J, Yan Y, Liu G, Sang X, Wu X, Gao Y, Xia X, Yu X, Pan J, Gao GF, Zhou J.

J Virol. 2015 Sep;89(17):8806-15. doi: 10.1128/JVI.00653-15. Epub 2015 Jun 17.

13.

The nucleoprotein of newly emerged H7N9 influenza A virus harbors a unique motif conferring resistance to antiviral human MxA.

Riegger D, Hai R, Dornfeld D, Mänz B, Leyva-Grado V, Sánchez-Aparicio MT, Albrecht RA, Palese P, Haller O, Schwemmle M, García-Sastre A, Kochs G, Schmolke M.

J Virol. 2015 Feb;89(4):2241-52. doi: 10.1128/JVI.02406-14. Epub 2014 Dec 10.

14.

Global alert to avian influenza virus infection: from H5N1 to H7N9.

Poovorawan Y, Pyungporn S, Prachayangprecha S, Makkoch J.

Pathog Glob Health. 2013 Jul;107(5):217-23. doi: 10.1179/2047773213Y.0000000103. Review.

15.

Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets.

Chen Z, Baz M, Lu J, Paskel M, Santos C, Subbarao K, Jin H, Matsuoka Y.

J Virol. 2014 Jun;88(12):7016-23. doi: 10.1128/JVI.00100-14. Epub 2014 Apr 9.

16.

A novel approach for preparation of the antisera reagent for potency determination of inactivated H7N9 influenza vaccines.

Schmeisser F, Jing X, Joshi M, Vasudevan A, Soto J, Li X, Choudhary A, Baichoo N, Resnick J, Ye Z, McCormick W, Weir JP.

Influenza Other Respir Viruses. 2016 Mar;10(2):134-40. doi: 10.1111/irv.12365. Epub 2016 Jan 29.

17.

Development of influenza A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs.

Ridenour C, Johnson A, Winne E, Hossain J, Mateu-Petit G, Balish A, Santana W, Kim T, Davis C, Cox NJ, Barr JR, Donis RO, Villanueva J, Williams TL, Chen LM.

Influenza Other Respir Viruses. 2015 Sep;9(5):263-70. doi: 10.1111/irv.12322.

18.

Pandemic potential of avian influenza A (H7N9) viruses.

Watanabe T, Watanabe S, Maher EA, Neumann G, Kawaoka Y.

Trends Microbiol. 2014 Nov;22(11):623-31. doi: 10.1016/j.tim.2014.08.008. Epub 2014 Sep 25. Review.

19.

Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.

Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF 3rd, Glenn GM.

Vaccine. 2013 Sep 13;31(40):4305-13. doi: 10.1016/j.vaccine.2013.07.043. Epub 2013 Jul 26.

20.

H7N9: a low pathogenic avian influenza A virus infecting humans.

Liu J, Xiao H, Wu Y, Liu D, Qi X, Shi Y, Gao GF.

Curr Opin Virol. 2014 Apr;5:91-7. doi: 10.1016/j.coviro.2014.03.001. Epub 2014 Apr 3. Review.

PMID:
24705093

Supplemental Content

Support Center